Report Overview

The Brazil Lung Cancer Therapeutics Market size stood at USD xx million in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The lung cancer decreases the ability of lungs to supply oxygen to the bloodstream. In Brazil, lung cancer is the second most common cancer in men and the fourth most common cancer in women, with 18,740 and 12,530 new cases, respectively. It is the leading cause of death due to cancer in men and the second such leading cause in women. The prominent symptoms indicating lung cancer include coughing, wheezing, weight loss, chest pain, body mucus, shortness of breath, appetite loss.



Market Drivers

The market is expected to have a high growth rate on account of growing number of people suffering from lung cancer. Air pollution, amplified alcohol consumption, varying lifestyle, smoking, unhealthy food, and no physical activity are the factors driving the market. Brazilian government initiative for providing awareness among the people about cancer.

Furthermore, factors such as targeted and ground-breaking delivery of drugs to the lung coupled with rising acceptance of personalized treatments are also seen to be an important factor driving the market of lung cancer therapeutics.